INTRODUCTION
============

Sensorineural hearing loss (SNHL) is a common disability. It includes age-related hearing loss, noise-induced hearing loss, genetic hearing loss, sudden sensorineural hearing loss (SSHL), and hearing loss caused by ototoxic drugs (for example, aminoglycosides). In the United States, about 63% of people older than 70 years have hearing loss ([@B45]). Profound, early onset deafness is found in 4--11 per 10,000 children and in 50% of such cases, the causes are genetic ([@B48]). SSHL occurs in 5--20 cases per 100,000 persons annually ([@B12]). Despite the high prevalence, no effective treatment has been established for SNHL, except for cochlear implants in profound SNHL or steroid treatment in the cases of acute hearing loss, such as SSHL. Most SNHL cases are caused by the loss or functional impairment of hair cells (HCs) in the cochlea, but mammalian HCs have not been considered to be capable of proliferation during postnatal stage ([@B61]). Consequently, HCs never regenerate in the cochlea, a hearing organ in the inner ear, although HCs in the vestibular organs (utricle and saccule) in the inner ear have minimal capacity for regeneration ([@B20]; [@B73]). This fact has prevented development of effective methods for treating SNHL. In contrast to mammals, avian inner ear HCs have been shown to be able to regenerate even after birth ([@B18]; [@B33]; [@B62]). Regeneration of avian HCs is based on both proliferation ([@B18]; [@B62]) and transdifferentiation ([@B2]; [@B6]) of supporting cells (SCs) that surround HCs. Thus, SCs are considered to be a source of HC regeneration.

As regenerative medicine emerged in the 21st century, many researchers have attempted to regenerate mammalian HCs using various strategies: stem cell transplantation, overexpression of specific genes, and treatment with growth factors. Tissue-engineering technology, which is one of the most powerful tools of regenerative medicine, is based on three important factors, namely, isolated cells, tissue-inducing substances, and scaffold or matrices into which cells are placed ([@B38]), all of which are also necessary for regenerative medicine.

Tissue-inducing substances also include growth factors, which are humoral factors that bind to their specific receptors on the cell membrane to activate intracellular signaling in order to exert their effects. Since growth factors were first extracted from exocrine or endocrine organs in the 1960's and 1970's ([@B17]; [@B4]), they have been demonstrated to regulate survival, proliferation, and differentiation of various types of cells in various organs. These functions prompted the application of some growth factors to regenerative medicine. For instance, basic fibroblast growth factor enhances proliferation of epidermal cells, inspiring its use in the treatment of pressure ulcers and other types of skin ulcer. From the study of hematopoietic stem cells and various precursor cells of the hematopoietic system, various growth factors have been identified as regulating the induction and proliferation of specific lineages of hematopoietic cells. Among these growth factors, erythropoietin and granulocyte-colony stimulating factor are clinically used to treat anemia and neutropenia, respectively. These are good examples of the application of growth factors in regenerative medicine.

In this article, after first briefly reviewing the role of growth factors, particularly insulin-like growth factor-1 (IGF-1), in the inner ear, we summarize the application of IGF-1 to the treatment of inner ear disorders in animal models, the mechanisms underlying the effects of IGF-1 on the inner ear, and a clinical trial of IGF-1 in human SSHL cases.

GROWTH FACTORS AND THE INNER EAR
================================

It has been investigated whether growth factors could induce proliferation of HCs, which have been reported to lose their proliferative ability from the embryonic stage ([@B61]). Growth factors were expected to induce HC proliferation during the postnatal stage because they have a marked capacity for inducing proliferation in treated cells. When neonatal rat utricle cells were dissociated and cultured, the effect of various types of growth factors on the proliferation of utricular cells was investigated quantitatively ([@B81]). Among several growth factors tested, epidermal growth factor, transforming growth factor α, basic fibroblast growth factor, and IGF-1 were able to induce proliferation. In particular, combination of basic fibroblast growth factor and IGF-1 or transforming growth factors α had additive effects. Similar mitogenic effects were confirmed for epidermal growth factor and transforming growth factor α in vestibular organ culture ([@B37]; [@B78]). Moreover, epidermal growth factor caused supernumerary HC formation even in neonatal mouse cochlear organ culture ([@B42]).

INSULIN-LIKE GROWTH FACTOR-1 AND ITS DOWNSTREAM SIGNALING
=========================================================

Insulin-like growth factor-1 was originally found in human serum as a factor that stimulates the incorporation of sulfate into cartilage ([@B63]). Later, it was shown that its insulin-like activity was not suppressed by anti-insulin antibodies ([@B21]) although its structure was similar to that of proinsulin ([@B57]). The insulin-like activity of IGF-1 was 60 times lower than that of insulin but, in contrast, the \[^3^H\]-thymidine incorporation activity (proliferation-induction activity) of IGF-1 was 50 times higher than that of insulin ([@B58]). IGF-1 is a small peptide, comprising 70 amino acids ([@B59]), which acts as an anabolic and mitogenic effector of growth hormone ([@B39]). IGF-1 in the serum is synthesized mainly in the liver and most of the circulating IGF-1 forms a complex with its binding proteins, IGFBP1--6 ([@B32]) that modify the activity of IGF-1.

Insulin-like growth factor-1 exerts its action through its receptor, IGF1 receptor (IGF1R). IGF1R belongs to a family of tyrosine kinase receptors. Once IGF-1 binds to IGF1R, it induces autophosphorylation on the intracellular tyrosine residues ([@B34]; **Figure [1](#F1){ref-type="fig"}**). Activated IGF1R interacts with and phosphorylates other intracellular adaptor molecules, viz., the insulin receptor substrate (IRS) 1--4 and Src homology collagen (Shc) protein ([@B50]; [@B10]; [@B75]). Phosphorylated IRSs activate phosphatidylinositol-3 kinase (PI3K) and lead to the formation of membrane-associated phosphorylated inositols. These molecules activate phosphoinositide-dependent kinase, which phosphorylates several other protein kinases, such as Akt (PI3K/Akt pathway; **Figure [1](#F1){ref-type="fig"}**) and protein kinase C ([@B68]). PI3K activation is involved in the inhibition of apoptosis, regulation of gene transcription, and mitogenesis ([@B67]). IGF1R activates another pathway through the recruitment to both IRS-1 and Shc of Sos via the SH2 domain of Grb2 ([@B79]). This recruitment leads to the activation of the small G-protein, Ras, which in turn causes the activation of Raf. Raf phosphorylates MAPK/ERK kinase (MEK) and MEK activates the extracellular-signal-regulated kinase (ERK) in the MEK/ERK pathway (**Figure [1](#F1){ref-type="fig"}**; [@B40]). This pathway is mainly involved in mitogenic ([@B55]), transcriptional ([@B40]), or anti-apoptotic responses ([@B27]; [@B19]).

![**Graphical summary of the signaling pathways of IGF-1 and its downstream effectors, and its effect on the protection of hair cells (HC~**S**~).** The mechanisms of HC number maintenance by IGF-1 were elucidated using several specific inhibitors (LY294002, Akt inhibitor VIII, U0126, and PD98059) of the downstream molecules in IGF-1 signaling pathways. IGF-1 protects HC~S~ against aminoglycosides through activation of both the MEK/ERK and PI3K/AKT pathways. Akt is involved in the survival of only inner HC~S~. MEK/ERK causes cell cycle promotion in Hensen's and Claudius' cells.](fphar-05-00208-g001){#F1}

As an effector of growth hormone, IGF-1 is involved in the anabolic growth of various organs. In addition to this original role, IGF-1 also regulates, for example in the central nervous system, neuronal survival, neurogenesis, angiogenesis, excitatory, and inhibitory neurotransmission, regulation of food intake, and cognition ([@B74]). Since recombinant IGF-1 has been synthesized, it has been used clinically in replacement therapy in patients with primary growth hormone-resistance (Laron syndrome) where IGF-1 is not synthesized ([@B39]). However, recombinant IGF-1 has been evaluated clinically for the treatment of other diseases. It has been reported to reduce the requirement for insulin in type I diabetes mellitus, to reduce the serum levels of lipoproteins, to increase the glomerular filtration and the tubular reabsorption of phosphate, and to slow the progression of amyotrophic lateral sclerosis ([@B39]). However, because the mitogenic effects of IGF-1 are involved in the growth regulation of breast ([@B76]) and prostate cancer ([@B16]; [@B72]) and because patients with IGF-1 hypersecretion (acromegaly) have a higher incidence of large bowel polyposis, the use of recombinant IGF-1 should be avoided in such patients or in those with a family history of these tumors.

IGF-1 AND THE INNER EAR
=======================

Since [@B44] reported that IGF-1 promotes the growth of chicken otocysts by inducing cell proliferation during the early developmental stage of the inner ear, many studies have shown that IGF-1 and its signaling system plays important roles in the development or maintenance of the inner ear, and, as a result, in hearing. In human beings, SNHL occurs in patients with mutations in *Igf1* gene ([@B77]; [@B11]; [@B69]), primary IGF-1 deficiency ([@B5]), or low serum IGF-1 levels due to other genetic defects ([@B7]; [@B31]), indicating the importance of IGF-1 in hearing. Replacement therapy using recombinant IGF-1 rescues patients from the hearing loss in Laron syndrome ([@B5]). The SNHL in Laron syndrome patients is attributed to cochlear dysfunction, based on otoacoustic emission test results ([@B5]). However, in a mouse model of IGF-1 deficiency, that is in IGF-1 knockout mice ([@B13], [@B14]; [@B15]; [@B60]), the causes of SNHL were reported as the loss of spiral ganglion neurons, abnormal myelination of the cochlear nerve, and degeneration of the stria vascularis, based on the results of morphological ([@B13], [@B14]) and auditory brain stem response studies ([@B15]; [@B60]). The stria degeneration becomes apparent from the age of 3 months in IGF-1 knockout mice although the loss of spiral ganglion cells commences from the age of 3 weeks ([@B14]; [@B60]). Knocking out of *Irs2*, a gene encoding an intracellular adaptor molecule of IGF1R, also showed similar inner ear phenotypes to IGF-1 knockout mice ([@B49]). In contrast to IGF-1 knockout mice, deletion of *Igfr1* caused inner ear anomalies (short cochlear duct, truncated lateral semicircular canal, and hypomorphic posterior semicircular canal), the delay of maturation of HCs and SCs in the cochlea, and reduced proliferation of prosensory cells in the development of the inner ear ([@B54]). Unfortunately, hearing phenotypes and mature inner ear morphology could not be studied because of the embryonic lethality caused by *Igf1r* knockout. Comparable phenotypes were reproduced with the treatment of IGF1R inhibitors on the embryonic cochlear explant culture. These IGF1R-mediated effects were observed in the middle to late stage of cochlear development and were dependent on the PI3K/Akt pathway but not on the MEK/ERK pathway, as indicated by detection of phosphorylated downstream of IGF1R and by inhibitor experiments ([@B54]). In contrast, the growth and proliferative effects of IGF-1 on otocysts and its survival effects in proliferative otic neuroblasts during the early developmental stage were dependent on the MEK/ERK pathway ([@B43]; [@B65]; [@B46]) and the PI3K/AKT pathway ([@B1]), respectively. The effector molecules of IGF-1 in the late stage of cochlear development have been studied using comprehensive gene expression analysis; several transcriptional factors (FoxM1, Mef2a, and Mef2d) have been identified as effectors of IGF-1 signaling ([@B64]).

The physiological functions of IGF-1 and its downstream signaling included the induction of proliferation in the development of the inner ear. Since postnatal inner ear HCs or SCs lose their proliferation potency, particularly in the cochlea ([@B61]), and as that prevents the regeneration of mammalian HCs after birth, IGF-1 may contribute to postnatal HC regeneration in mammals. Additionally, survival effects (anti-apoptotic effects) may contribute to the prevention of HC death after exposure to several types of conditions that cause inner ear pathology, including noise, ischemia, and toxic drug treatment, because these conditions usually cause apoptosis in HCs. Addition of IGF-1 to explant cultures of mature avian vestibular epithelia caused three-fold upregulation of DNA synthesis after a 48-h treatment but the numbers of \[^3^H\]-thymidine-incorporating cells were similar between 5-h- and 2-day-treatments, suggesting that IGF-1 did not contribute to the survival of the sensory epithelium ([@B53]). Explant cultures of avian auditory epithelia did not show this increase in DNA synthesis ([@B53]). Induction of proliferation was observed in neonatal rat dissociated vestibular SCs that had been treated with IGF-1 although other growth factors, including epidermal growth factor and transforming growth factor α, did not show any proliferative effects ([@B81]). This experiment suggested that IGF-1 was a candidate molecule for inducing regeneration of even postnatal mammalian inner ear HCs.

Explant culture of adult mammalian cochlea causes loss of outer HCs due to apoptosis even after a short culture period. Treatment with IGF-1 as well as acidic fibroblast growth factor, epidermal growth factor, and transforming growth factors β1 prevented the loss of outer HCs, suggesting the survival effect of IGF-1 on mature mammalian outer HCs ([@B47]). The survival effect of IGF-1 against aminoglycoside-induced severe HC loss was observed in explant cultures of postnatal mammalian utricle ([@B56]; [@B3]) and *in vivo* vestibular systems of mature guinea pigs ([@B36]). In the case of the *in vivo* experiments, the perilymph of the mature guinea pig inner ear was infused with mixture of transforming growth factor α, IGF-1, and retinoic acid after injury induced by aminoglycoside, and functional as well as morphological recovery of HCs was observed ([@B36]).

*IN VIVO* APPLICATION OF IGF-1 FOR COCHLEAR DAMAGE
==================================================

The successful application of IGF-1 to the treatment of aminoglycoside-induced mammalian vestibular HC damage suggested that IGF-1 was an effective molecule for use in inner ear disorders. However, unilateral peripheral vestibular damage can be compensated by the central nervous system and the demand for treatment of an affected vestibular system is less than in the case of the auditory system, where compensation never occurs. Moreover, unlike in the cochlea, mature mammalian vestibular sensory epithelia have the capacity to regenerate ([@B20]; [@B73]) although this capacity is not markedly strong. Treatment of cochlear damage is more challenging. In a study of vestibular systems, IGF-1 was delivered as single recombinant molecule, because IGF-1 is a relatively stable molecule compared with insulin. However, the half-life of IGF-1 is about 8--16 h ([@B39]). For inner ear treatment, local application of IGF-1 is a more preferable drug delivery method compared with systemic delivery, because blood flow of inner ears is only 1/10000 to 1/1000000th of the systemic flow. Considering these conditions, gelatin hydrogel ([@B80]) has been used to achieve efficient local application of IGF-1 into the animal or human cochlea ([@B28]; [@B41]; [@B22]; [@B52]). In a gelatin hydrogel drug delivery system, sufficient IGF-1 levels are detected in the perilymph until at least 3 days after application of IGF-1 within the hydrogel to the round window of the cochleae ([@B41]).

First of all, IGF-1 was applied 3 days prior to noise exposure in mature rat ([@B28]). Threshold shifts for 16 and 32 kHz were significantly smaller in the IGF-1 group at 7 days after noise exposure. Histological evaluation showed that outer HC loss was significantly milder in all turns of the cochleae in the IGF-1 group than in the control group. These results indicated that local application of IGF-1 had positive effects on the protection of outer HCs against noise exposure and, in turn, caused reduced threshold shifts in the hearing ability of adult rats. Next, IGF-1 was applied into the adult guinea pig cochlea 5 h after noise exposure ([@B41]). It is important to confirm whether the treatment had effects even after noise exposure because prophylactic application of a drug is sometimes difficult in clinical practice. Similar to the previous study, threshold shifts due to noise exposure were significantly attenuated and outer HC cell loss was also significantly reduced by the IGF-1 treatment. These two experiments clearly showed that IGF-1 application using gelatin hydrogel was a promising candidate treatment for noise-induced hearing loss.

Insulin-like growth factor-1 application has also been studied in a cochlear ischemia and reperfusion injury model in Mongolian gerbils ([@B22]), which represents hearing loss similar to sudden deafness in humans ([@B23]; [@B35]). In this study, threshold shifts, assessed by auditory brain stem response, were significantly attenuated in an IGF-1-treatment group, similar to that observed in the noise exposure model. However, there were some points of difference between the effects of IGF-1 on noise exposure and ischemic injuries of the cochlea. First, threshold attenuation occurred 1 day after the injury in the ischemic and reperfusion model. In contrast, it occurred only 14 days after noise exposure. Second, rescued HC types were different between these two conditions: inner and outer HC loss was attenuated in ischemic and noise exposure models, respectively. These results suggested several points about the effect of IGF-1 on SNHL. (1) IGF-1 has the ability to affect both the early and late phase of SNHL. (2) IGF-1 treatment has potency to protect both inner and outer HCs from damage. (3) IGF-1 has effects on different mammals, viz., rats, guinea pigs, and Mongolian gerbils.

MECHANISMS BY WHICH HC NUMBERS ARE MAINTAINED BY IGF-1 TREATMENT
================================================================

Cochlear explant culture systems are suitable for analyzing the mechanisms underlying treatment effects because timing of drug application or sample collection is easier to control than *in vivo* experimental models. Therefore, the mechanisms underlying the positive effects of IGF-1 on cochlear HCs were evaluated using cochlear explant cultures ([@B24]). In this system, cochlear explant cultures were established from neonatal mice and aminoglycoside was used to induce damage to HCs. IGF-1 treatment resulted in the maintenance of both inner and outer HC numbers after aminoglycoside treatment, which was similar to its effects on noise exposure and ischemic injury in *in vivo* experiments. Specific inhibitors of PI3K, Akt, or ERK were used with IGF-1 to elucidate which downstream signaling pathways of IGF1R were involved in the protective effects of IGF-1 (**Figure [1](#F1){ref-type="fig"}**). Different agents were used to inhibit either the PI3K/Akt or MEK/ERK pathways. The PI3K inhibitor, LY294002, and the Akt inhibitor, Akt inhibitor VIII, were used to inhibit the PI3K/Akt pathway. For the MEK/ERK pathway, two different ERK inhibitors (U0126 and PD98059) were used. Either treatment caused attenuation of HC-protection effects, indicating that both pathways were involved in the maintenance of HC numbers. These results are different from the roles of IGF-1 in the development the cochlea, where only the PI3K/Akt pathway was involved at a later stage ([@B54]), and suggested that treatment with IGF-1 is a more efficient method for protecting HCs than the activation of a single signal cascade although the activation of a single pathway is effective for HC protection ([@B8]; [@B30]; [@B66]). Among several inhibitors used, Akt inhibitor treatment attenuated only the inner HC protection effect, suggesting that Akt is involved in only the maintenance of inner HCs. A study of the localization of phosphorylated Akt and phosphorylated ERK using antibodies to these molecules determined that both Akt and ERK were activated not in HCs, but in SCs. Akt was activated in the inner sulcus cells that are located adjacent to inner HCs. In contrast, ERK was activated in Hensen's and Claudius' cells that are located lateral to the outer HCs. The localization of phosphorylated Akt-positive cells was consistent with the experiment in which an Akt inhibitor was used and indicated that Akt is an important signal for the protection of inner HCs. These results also raised the question about how IGF-1 protected HCs. One of the hypotheses is that IGF-1 acts on SCs and SCs, in turn, secrete some factors or express signal-transducing proteins on the membrane and these factors or proteins induce HC maintenance or regeneration.

There are two possible mechanisms involved in the maintenance of HC numbers. One is the inhibition of cell death and the other is the proliferation of HCs themselves or transdifferentiation of SCs into HCs after SC proliferation. Involvement of these two mechanisms has also been studied using cochlear explant cultures ([@B24]). These results showed that apoptosis of HCs was significantly inhibited in the IGF-1-treated group and, surprisingly, induction of cell-cycle promotion was also observed in the epithelium of postnatal cochlear explants. The latter result was inconsistent with the physiological characteristics of postnatal mammalian cochleae, but cell cycle promotion was confirmed by two different methods, i.e., 5-bromo-2′-deoxyuridine (BrdU) incorporation and phosphohistone H3 immunostaining. In addition, treatment with two different proliferation inhibitors, aphidicolin or L-mimosine, caused attenuation of only outer HC number maintenance. Together with the finding that all BrdU-positive cells were observed in Hensen's and Claudius' cells adjacent to outer HCs, this indicated that promotion of the cell cycle in the cochlea by IGF-1 contributed to maintenance of the outer HCs only and that transdifferentiation of SCs into HCs after SC proliferation may be the mechanism involved. The MEK/ERK pathway is likely to be involved in the cell cycle promotion in Hensen's and Claudius' cells, as deduced from two findings: phosphorylated ERK, which indicates the activation of the MEK/ERK pathway, was detected in Hensen's and Claudius' cells where BrdU incorporation and phophohistone H3 were detected, and the proliferation of SCs was caused by activation of the MEK/ERK pathway in chicken basilar papillae, resulting in the regeneration of HCs ([@B9]).

The target molecules of by which IGF-1 maintains the numbers of HCs were identified using comprehensive analysis of gene expression in explant cultures treated with IGF-1 ([@B25]). The expression of two molecules, Netrin1 and Gap43, was significantly up-regulated in the IGF-1-treated group and the result was confirmed by quantitative reverse transcriptase-polymerase chain reaction. Upregulation of gene expression was reduced by inhibition of both the MEK/ERK and PI3K/AKT pathways, indicating that the target molecules of IGF-1 were regulated by both pathways. Netrin1 is a secreted molecule that exerts its effects through its specific receptors. Originally, it was described as being involved in axon guidance of the nervous system ([@B26]), but recent reports have shown its beneficial effects in injured organs, including the kidney. In the kidney, translation of Netrin1 is induced in response to reperfusion injury through the activation of the MEK/ERK pathway ([@B29]), and Netrin1 increases the proliferation and migration of renal proximal tubular epithelial cells ([@B71]). Moreover, overexpression of Netrin1 protects the kidney from ischemia and reperfusion injury ([@B70]). Since the effect of HC protection by IGF-1 was achieved through cell cycle promotion and inhibition of apoptosis ([@B24]), Netrin1 is the probable effector molecule of IGF-1 during cochlear HC protection.

CLINICAL TRIAL OF IGF-1 FOR SSHL
================================

Based on these *in vivo* and *in vitro* studies, a clinical trial was performed to study the efficacy of IGF-1 in the treatment of SNHL (University Hospital Medical Information Network Clinical Trials Registry under trial registration number UMIN000000936; [@B52], [@B51]). In this clinical trial, 25 patients with SSHL that was refractory to systemic steroid therapy were recruited and IGF-1 was applied onto the round window membrane, using gelatin hydrogel, as performed in *in vivo* animal studies ([@B28]; [@B41]; [@B22]). The outcome of IGF-1 treatment was compared with that of a historical control after hyperbaric oxygen therapy where 66 out of 199 patients (33%) showed the hearing threshold improvement ([@B52]). In this trial, improvement of hearing threshold was defined as recovery of more than 10 dB in the mean hearing level at the five frequencies tested (0.25, 0.5, 1.0, 2.0, and 4.0 kHz). At 12 and 24 weeks after IGF-1 treatment, the proportions of patients showing hearing improvement was 48 and 56%, respectively. No serious adverse effects were observed. The proportion of hearing improvement at 24 weeks after IGF-1 treatment was significantly better than that of the historical control. Analyses of recovery of threshold in each frequency tested revealed that the thresholds for lower frequencies recovered better than those for higher frequencies ([@B51]). Average recovery in pure tone audiometry thresholds over the five frequencies tested was 11.9 dB ([@B51]), which was comparable to the average threshold recovery previously reported for intra-tympanic steroid injection (5--22 dB). A randomized clinical trial, comparing the efficacy of topical IGF-1 treatment with that of intra-tympanic steroids for SSHL that is refractory to systemic steroids, is now underway, involving about 120 patients from all over Japan (University Hospital Medical Information Network Clinical Trials Registry under trial registration number UMIN000004366).

CONCLUSION
==========

In conclusion, IGF-1 is a promising medication for SNHL. IGF-1 activates both its downstream signaling pathways, the MEK/ERK and PI3K/Akt pathways in the cochlea, which causes more efficient effects on HC protection than activation of a single signal cascade. IGF-1 protects HCs from various injuries to the inner ear, including noise exposure, ischemia, and aminoglycoside treatment. A clinical trial of IGF-1 treatment on human SSHL as well as *in vivo* animal experiments has confirmed its efficacy against HC injuries.
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